4D Molecular Therapeutics Inc. Stock Price, News & Analysis

4D Molecular Therapeutics (Nasdaq: FDMT) has announced the granting of employment inducement awards to eight new non-executive employees. On May 13, 2025, the company's compensation committee approved the issuance of 31,800 Restricted Stock Units (RSUs) under its 2025 Employment Inducement Award Plan. This plan was established in February 2025 and approved by the board of directors in compliance with Nasdaq Global Market Rule 5635(c)(4), which specifically allows for equity grants as employment inducements for new hires.

4D Molecular Therapeutics (FDMT) reported Q1 2025 financial results and key operational updates. The company has enrolled first patients in its 4D-150 Phase 3 clinical trial (4FRONT-1) for wet AMD, with over 50 clinical sites active. A second Phase 3 trial (4FRONT-2) is expected to begin in Q3 2025, with topline data from both trials anticipated in H2 2027.

The company maintains a strong financial position with $458 million in cash and equivalents as of March 31, 2025, expected to fund operations into 2028. Q1 2025 saw a net loss of $48.0 million, with R&D expenses of $40.7 million and G&A expenses of $12.9 million.

Notable achievements include receiving RMAT designation for 4D-150 in DME and positive Phase 1/2 trial results showing an 83% reduction in injection burden for wet AMD patients. The company has focused its pipeline on core programs 4D-150 and 4D-710, while pausing several other programs to extend cash runway.

4D Molecular Therapeutics (FDMT), a late-stage biotechnology company, has announced its participation in two major healthcare investor conferences in May 2025. The company's management will engage in fireside chats at the BofA Securities 2025 Healthcare Conference on May 14 at 2:20 p.m. PT and the RBC Capital Markets 2025 Global Healthcare Conference on May 21 at 9:00 a.m. ET. Management will also be available for one-on-one meetings with investors. Webcasts of both presentations will be accessible through the company's investor relations website for up to one year.

4D Molecular Therapeutics (FDMT) has achieved a significant milestone as the FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to 4D-150 for treating diabetic macular edema (DME). This marks 4D-150 as the first investigational medicine to receive RMAT designation for both DME and wet age-related macular degeneration (wet AMD). The designation, based on results from the ongoing SPECTRA DME study, suggests 4D-150's potential to maintain visual acuity improvements while reducing treatment burden. The RMAT status, part of the 21st Century Cures Act, will expedite development through enhanced FDA interaction. The company plans to advance 4D-150 into Phase 3 development with a single trial for DME approval, alongside two wet AMD 4FRONT Phase 3 clinical trials.

4D Molecular Therapeutics (Nasdaq: FDMT) has announced employment inducement grants for three new non-executive employees. The compensation committee approved the issuance of 16,500 Restricted Stock Units (RSUs) on April 8, 2025.

The RSUs were granted under the Company's 2025 Employment Inducement Award Plan, which was established in February 2025. This plan operates under Rule 5635(c)(4) of The Nasdaq Global Market, specifically designed for equity grants to attract new employees to the company.

4D Molecular Therapeutics (Nasdaq: FDMT), a late-stage biotechnology company, has announced its participation in the upcoming RBC Capital Markets 2025 Ophthalmology Conference. The virtual event is scheduled for April 3-4, 2025, where the company's management will engage in a fireside chat and be available for one-on-one meetings.

The company, focused on developing durable and disease-targeted therapeutics, aims to transform treatment paradigms. Interested parties can access an archived recording of the webcast for up to one year through the 'Investors' section on 4DMT's website.

4D Molecular Therapeutics (FDMT) has announced the enrollment of first patients in its 4FRONT-1 Phase 3 clinical trial evaluating 4D-150 for wet age-related macular degeneration (wet AMD) treatment. The trial is a multicenter, randomized, double-masked study comparing 4D-150 with aflibercept 2 mg.

The primary endpoint aims to demonstrate non-inferiority in mean change from baseline in best corrected visual acuity at 52 weeks. A key secondary endpoint focuses on reducing treatment burden by comparing the number of aflibercept injections between treatment arms.

The company plans to initiate 4FRONT-2, a second Phase 3 trial with identical design, in Q3 2025. Topline primary endpoint data from both trials is expected in the second half of 2027. The treatment aims to address the challenge of frequent eye injections while preserving eyesight for millions of wet AMD patients.

4D Molecular Therapeutics (FDMT) reported its full year 2024 financial results with significant progress in its clinical programs. The company highlighted positive interim data for 4D-150 in wet AMD and DME treatments, showing robust clinical activity and durability.

Key financial metrics include $505 million in cash and equivalents as of December 31, 2024, expected to fund operations into 2028. The company reported a net loss of $160.9 million for 2024, compared to $100.8 million in 2023. R&D expenses increased to $141.3 million from $97.1 million in 2023.

The company plans to initiate Phase 3 trials (4FRONT-1 and 4FRONT-2) for wet AMD in March and Q3 2025 respectively, with topline data expected in H2 2027. FDA alignment was achieved for a single Phase 3 trial for DME treatment.

4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage company specializing in genetic medicines for large market diseases, has announced its participation in two major investor conferences in March 2025.

The company will engage in fireside chats at Leerink's Global Biopharma Conference on Tuesday, March 11, 2025, at 10:00 a.m. ET, and at the Barclays Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET. Management team members will be available for one-on-one meetings during both events.

Webcasts of both presentations will be accessible through the company's website, with archived versions remaining available for up to one year in the 'Investors' section at ir.4dmoleculartherapeutics.com/events.